United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - rifampicin - oral capsule - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - rifampicin - oral capsule - 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - rifampicin - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rifampicin - oral capsule - 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow - arcoxia is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenylephrine hydrochloride, quantity: 5 mg/ml - spray, solution - excipient ingredients: purified water; sodium chloride; sodium hydroxide; thiomersal; hydrochloric acid; sodium citrate dihydrate - relieves nasal congestion in colds, flu, allergy, hayfever and sinusitis.

Malta - English - Medicines Authority

central procurement & supplies unit - rifampicin - capsule - rifampicin 300 mg - antimycobacterials